Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological disorders such as Alzheimer’s, Parkinson’s, and chronic traumatic encephalopathy.

Pharmaceutical

Samus Therapeutics

Richard Bagley

Barbara Wallner

John Amedio

Marc Swikalus

Robert Morgan

Gregory Hileman

Stacey Channing

Sharlene Cirillo

Michael H. Silverman

Leadership Team

Teams at Samus Therapeutics

Leadership Team